Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).
Gerd-Rüdiger R BurmesterFilip E Van den BoschDiamant ThaҫiAnna K ShmagelYanxi LiuNasser KhanHeidi S CampAlan J KivitzPublished in: The Journal of rheumatology (2024)
The 5-year benefit-risk profile for UPA in RA remains favorable. (SELECT-NEXT; ClinicalTrials.gov: NCT02675426).